Ken Griffin
TAK icon

Ken Griffin’s Takeda Pharmaceutical TAK Stock Holding History

Ken Griffin’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Buy
624,160
+234,426
+60% +$4.11M ﹤0.01% 3052
2025
Q4 		$6.08M Buy
389,734
+314,110
+415% +$4.49M ﹤0.01% 3978
2025
Q3 		$1.11M Buy
+75,624
New +$1.12M ﹤0.01% 7317
2025
Q2 		– Sell
-142,556
Closed -$2.11M – 15019
2025
Q1 		$2.12M Buy
142,556
+104,567
+275% +$1.47M ﹤0.01% 5424
2024
Q4 		$503K Buy
+37,989
New +$522K ﹤0.01% 8542
2024
Q3 		– Sell
-312,081
Closed -$4.43M – 15226
2024
Q2 		$4.04M Buy
312,081
+302,886
+3,294% +$4.01M ﹤0.01% 4085
2024
Q1 		$128K Sell
9,195
-86,564
-90% -$1.26M ﹤0.01% 11016
2023
Q4 		$1.37M Buy
95,759
+92,068
+2,494% +$1.31M ﹤0.01% 6060
2023
Q3 		$57.1K Sell
3,691
-44,584
-92% -$690K ﹤0.01% 11593
2023
Q2 		$758K Sell
48,275
-7,741
-14% -$127K ﹤0.01% 7033
2023
Q1 		$923K Buy
56,016
+36,273
+184% +$578K ﹤0.01% 6956
2022
Q4 		$308K Sell
19,743
-678,082
-97% -$9.47M ﹤0.01% 9263
2022
Q3 		$9.05M Buy
697,825
+296,059
+74% +$4.12M ﹤0.01% 2911
2022
Q2 		$5.64M Buy
401,766
+58,083
+17% +$829K ﹤0.01% 3574
2022
Q1 		$4.92M Sell
343,683
-18,335
-5% -$269K ﹤0.01% 4202
2021
Q4 		$4.93M Sell
362,018
-37,960
-9% -$532K ﹤0.01% 4315
2021
Q3 		$6.55M Buy
399,978
+76,288
+24% +$1.28M ﹤0.01% 3794
2021
Q2 		$5.45M Buy
323,690
+110,412
+52% +$1.88M ﹤0.01% 4248
2021
Q1 		$3.9M Sell
213,278
-140,122
-40% -$2.52M ﹤0.01% 4826
2020
Q4 		$6.43M Buy
353,400
+231,403
+190% +$4.06M ﹤0.01% 3253
2020
Q3 		$2.18M Buy
121,997
+15,394
+14% +$280K ﹤0.01% 4562
2020
Q2 		$1.91M Sell
106,603
-98,434
-48% -$1.77M ﹤0.01% 4666
2020
Q1 		$3.11M Buy
205,037
+108,154
+112% +$1.96M ﹤0.01% 3403
2019
Q4 		$1.91M Sell
96,883
-98,211
-50% -$1.88M ﹤0.01% 4488
2019
Q3 		$3.36M Buy
195,094
+25,788
+15% +$446K ﹤0.01% 3675
2019
Q2 		$3M Buy
169,306
+121,028
+251% +$2.2M ﹤0.01% 3859
2019
Q1 		$983K Sell
48,278
-528,806
-92% -$10.6M ﹤0.01% 5620
2018
Q4 		$9.71M Buy
+577,084
New +$9.74M 0.01% 1928

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ken Griffin's TAK Position: Q1 2026 in Review

Ken Griffin increased its Takeda Pharmaceutical (TAK) stake by 60% in Q1 2026, buying an estimated $4.11M and bringing the position to 624,160 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

Ken Griffin first reported a position in TAK in Q4 2018 and has held it in 28 quarters since. 360 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Ken Griffin held 624,160 shares of Takeda Pharmaceutical worth $11.6M as of Q1 2026.
  • Ken Griffin bought 234,426 Takeda Pharmaceutical shares in Q1 2026, an estimated $4.11M.
  • Takeda Pharmaceutical made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3052 holding.
  • Ken Griffin first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 28 quarters since.
  • 360 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.